IDEXX Laboratories, Inc. (IDXX)
IDEXX Laboratories is a global leader in pet healthcare, providing the diagnostic tests, software, and equipment that vets use to keep our furry friends healthy.
Is IDEXX Laboratories, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Strong profit margins showing a very efficient business model. Worth weighing: High valuation multiples suggest the shares are not cheap.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does IDEXX Laboratories, Inc. do?
IDEXX makes its money by selling the machines and lab services that help vets diagnose illnesses in pets quickly. Because pet owners are increasingly treating their animals like family members, the demand for high-quality medical care has been a steady engine for the company. The question that matters most is whether they can keep growing their diagnostic business as more pet owners seek advanced health insights for their companions.
On our factor screen it looks strongest on quality and growth, and weakest on value.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 10% over the year
- ✓Very profitable - turns about 25% of sales into profit
- !High P/E of 41 - big growth is already priced in
- ✓Strong return on shareholder money (ROE 74%)
- Quality screens high
- Value screens low
- Momentum screens low
- Income screens low
Does IDEXX Laboratories, Inc. pay a dividend?
No - IDEXX Laboratories, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does IDEXX Laboratories, Inc. have more cash or more debt?
It holds about $196.93M in cash against about $1.10B of debt - so it has net debt of about $899.15M. Debt is not automatically a problem - it funds growth - but it has to be serviced and repaid, which matters more when profits wobble.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do IDEXX Laboratories, Inc.'s numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-10. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has IDEXX Laboratories, Inc. actually fallen?
Over the last 2 years of daily prices, IDEXX Laboratories, Inc. fell as much as −34% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns IDEXX Laboratories, Inc.?
About 96% of IDEXX Laboratories, Inc., or about 96 in every 100 shares, is held by big institutions such as pension and index funds. The rest, roughly 4%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does IDEXX Laboratories, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Where does each £100 of IDEXX Laboratories, Inc.'s sales go?
A rough split of the latest full-year figures: of every £100 of sales, about £38 covers making the product or service, £37 goes on running costs, tax and interest, and about £25 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.
When does IDEXX Laboratories, Inc. report earnings, and how did recent quarters go?
IDEXX Laboratories, Inc. is next scheduled to report on about 2026-11-02 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-08-04 | $3.93 | $4.27 | Beat +9% |
| 2026-05-05 | $3.41 | $3.47 | Beat +2% |
| 2026-02-02 | $2.94 | $3.08 | Beat +5% |
| 2025-11-03 | $3.15 | $3.40 | Beat +8% |
| 2025-08-04 | $3.30 | $3.63 | Beat +10% |
| 2025-05-01 | $2.84 | $2.96 | Beat +4% |
Across the last 6 quarters here, IDEXX Laboratories, Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for IDEXX Laboratories, Inc.?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
IDEXX becomes the standard for all veterinary diagnostic software globally.
A long-term shift in consumer spending away from premium pet health services.
What are the pros and cons of IDEXX Laboratories, Inc.?
A balance check, not a score or verdict.
- Strong profit margins showing a very efficient business model
- High return on equity: How much profit the company makes for each £1 shareholders have put in. Higher usually means a more efficient business. indicates excellent use of capital
- Operates in a growing market as pet care becomes more advanced
- High valuation multiples suggest the shares are not cheap
- Does not pay a dividend, so no regular cash income for investors
- The share price can be quite volatile compared to the broader market
- Economic downturns could lead pet owners to cut back on non-essential vet visits
- Reliance on the veterinary industry means it is vulnerable to changes in vet staffing or clinic profitability
- Technological disruption from new, lower-cost diagnostic competitors
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained decline in the number of households owning pets
- A significant drop in the company's profit margins over several quarters
Common questions about IDEXX Laboratories, Inc.
Does IDEXX Laboratories, Inc. pay a dividend?
No - IDEXX Laboratories, Inc. does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does IDEXX Laboratories, Inc. report earnings next?
IDEXX Laboratories, Inc. is next scheduled to report results on about 2026-11-02. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
Charles River Laboratories International, Inc.
Baxter International Inc.
GSK
Haleon plc
AstraZeneca PLC
Convatec Group PLC
Beam Therapeutics Inc.
Tempus AI, Inc.Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.